Clinical research studyEfficacy of Short-Course Antibiotic Regimens for Community-Acquired Pneumonia: A Meta-analysis
Section snippets
Search Strategy
We used the Cochrane Central Register of Controlled Trials, Medline, and Embase to find publications from 1980 through June 2006. In the Cochrane database, the record title was searched for the keyword “pneumonia.” Articles in Medline and Embase were found by searching for clinical studies or trials with the word “pneumonia” in the title and without the following keywords in the title: “pneumocystis,” “aspiration,” “aspirate,” “nosocomial,” “ventilator,” “ventilation,” “ventilated,”
Description of Studies
Our search strategy identified more than 3700 potential references (Figure 1). Most studies were excluded due to the fact that they were not randomized controlled trials or did not compare a short-course versus an extended-course antibiotic regimen. Fifteen studies met our inclusion and exclusion criteria and were included in this meta-analysis (Table 1). These studies were published between 1990 and 2004 and comprised a total of 2796 subjects. Ten studies enrolled more than 100 participants
Discussion
In this meta-analysis, we found no significant differences between short-course and extended-course antibiotic regimens for the treatment of mild to moderate community-acquired pneumonia with respect to clinical success, mortality, bacteriologic success, and adverse events. The results were consistent across a wide range of analyses, including both the intention-to-treat and per-protocol patient populations, high-quality studies, and individual antibiotic classes. Both outpatients and
Acknowledgments
We thank Gloria Won for her invaluable advice on the Embase and Medline literature searches. We are grateful for the help Yoshio Hall and Delphine Tuot provided in translating articles.
References (59)
Epidemiology and etiology of community-acquired pneumonia
Infect Dis Clin North Am
(2004)- et al.
Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia
Chest
(2004) Community-acquired pneumonia
Lancet
(2003)- et al.
Five-day azithromycin in the treatment of patients with community-acquired pneumonia
Curr Ther Res Clin Exp
(1995) - et al.
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Control Clin Trials
(1996) - et al.
Azithromycin versus comparative therapy for the treatment of community acquired pneumonia
Int J Antimicrob Agents
(2004) - et al.
Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin
Respir Med
(2004) - et al.
Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors
Med Mal Infect
(2002) - et al.
Antimicrobial therapy of community-acquired pneumonia
Infect Dis Clin North Am
(2004) - et al.
Antimicrobial treatment of community-acquired pneumonia
Clin Chest Med
(2005)
Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea
J Clin Epidemiol
Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus
Med Clin North Am
Practice guidelines for the management of community-acquired pneumonia in adultsInfectious Diseases Society of America
Clin Infect Dis
Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting
Am J Med
Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis
BMJ
Guidelines for the management of adults with community-acquired pneumoniaDiagnosis, assessment of severity, antimicrobial therapy, and prevention
Am J Respir Crit Care Med
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults
Clin Infect Dis
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults
Clin Infect Dis
Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
Clin Infect Dis
Clinical practiceManagement of community-acquired pneumonia
N Engl J Med
Antibiotics for community acquired pneumonia in adult outpatients
Cochrane Database Syst Rev
Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials
Arch Intern Med
BTS guidelines for the management of community acquired pneumonia in adults
Thorax
Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections
J Antimicrob Chemother
Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia
Clin Infect Dis
Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course
J Chemother
Short-course treatment of community-acquired pneumonia
Clin Infect Dis
Short-course antimicrobial therapy for community-acquired pneumonia
Treat Respir Med
A prediction rule to identify low-risk patients with community-acquired pneumonia
N Engl J Med
Cited by (150)
Infectious Pulmonary Diseases
2024, Infectious Disease Clinics of North AmericaManagement of Non-Ventilated hospital acquired pneumonia
2024, Clinical Infection in PracticeShort-course antibiotic therapy for hospitalized patients with early clinical response in community-acquired pneumonia: a multicentre cohort study
2023, Clinical Microbiology and InfectionInfectious Pulmonary Diseases
2022, Emergency Medicine Clinics of North AmericaCitation Excerpt :Treatment duration varies based on the resolution of vital sign abnormalities, ability to eat, and normal mentation. IDSA recommends no less than 5 days of therapy in uncomplicated outpatient CAP, and several meta-analysis studies have demonstrated successful efficacy with 5 to 7 day treatment durations.5,8–10 Inpatient CAP treatment should also be not less than 5 days unless MRSA or P aeruginosa is involved, then it is not less than 7 days.
Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis
2022, Clinical Microbiology and InfectionCitation Excerpt :Our search strategy yielded a total of 1195 systematic reviews. Of those, 35 systematic reviews evaluating fixed shorter versus longer durations of antibiotic therapy were included (Fig. 1) [4,16–49]. Fifteen (46.8%) included studies evaluating respiratory tract infections (including upper and lower tract), seven (21.8%) were focused on urinary tract infections (including upper and lower tract) and five (15.6%) included all infectious diseases.